• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Patient Problems Bruise/Contusion (1754); Pain (1994)
Event Date 08/14/2023
Event Type  Injury  
Event Description
On (b)(6) 2023 i had received euflexxa injections in both knees.By the 2nd week, 2nd injection i had pain in my calves, almost a feeling of a pulled muscle.Told nurse at 2nd appointment.3rd injection, i had a lot more pain in my calves, told nurse, she told me she would discuss with doctor, never heard anything more.I left and by week 4, i was hurting very bad.I had some bruising showing on back of left calf.By week 5, bruising went from back of calf, below knee all the way to ankle and top of foot.I called and spoke with nurse.She discussed with doctor and told me it doesn't sound like anything from injections and i should contact primary care doctor, be checked for blood clots.I did and blood work came back normal and my doctor told me i needed to get back in touch with specialist.I called multiple times, left messages.3rd time i was told to come back in.This appointment was on (b)(6) 2023.Prior to this, i contacted manufacturer and fda.Extra blood work to rule out blood clots.I don't have any lab results.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EUFLEXXA
Type of Device
ACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
MDR Report Key18291279
MDR Text Key330221167
Report NumberMW5149022
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Other
Type of Report Initial
Report Date 12/02/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Was Device Available for Evaluation? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received12/07/2023
Patient Sequence Number1
Treatment
AJOVY.; FISH OIL.; IBUPROFEN.; MAGNESIUM.; POTASSIUM; SUMATRIPTAN (AS NEEDED).
Patient Outcome(s) Other;
Patient Age49 YR
Patient SexFemale
Patient Weight81 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-